A new study is reporting that a new drug called sarilumab may be able to ease symptoms and slow down joint destruction in rheumatoid arthritis (RA).
The year-long study involved 1,200 patients with active, moderate-to-severe rheumatoid arthritis. All patients had either not benefitted from currently available treatments or had not been able to tolerate them.
Rheumatoid Arthritis
Rheumatoid arthritis is a chronic inflammatory disease that causes pain, swelling, stiffness and loss of function in the joints.
Advertisement
Patients who received a 200 mg dose of Sarilumab every alternate week along with methotrexate experienced a 66 percent improvement in the symptoms of rheumatoid arthritis after six months. Patients who received a 150 mg dose of the new drug experienced a 58 percent reduction in symptoms like pain and swelling.
"The initial results from this trial look quite promising in terms of reducing painful symptoms," a spokesman for Arthritis Research UK told The Daily Mail. "Sarilumab is still under development and results of this study have not yet been published."
Sarilumab has been developed by Sanofi and Regeneron.
Source: Medindia
Sarilumab has been developed by Sanofi and Regeneron.
Source: Medindia
Osteoarthritis
Osteoarthritis is one of the commonest joint disorder and occurs as we age due to wear and tear of a joint. Osteoarthritis can affect any joint of the body.
Advertisement
 OligoarthritisMost parents when told that their child has arthritis find it hard to believe it, as arthritis is regarded an adult's disease. | Advertisement
|
Hip replacement
Are you experiencing pain due to damaged hips? Travel abroad to get replacement surgery at affordable prices.
Advertisement
Recommended Reading
Latest Clinical Trials News
Erdafitinib is the first approved FGFR-targeted treatment for advanced urothelial cancer, reveal scientists.
Amyotrophic lateral sclerosis patients' motor neurons responded robustly to Parkinson's drug ropinirole.
A new way to quickly eliminate fungal infections in the mouth has been developed by researchers at Penn Dental and Penn Engineering, using magnetically guided nanorobots.
Researchers tested the effectiveness of virus-mediated gene therapy for genetic hearing loss in an aged mouse model with genetic changes related to deafness.
The outcomes of the first clinical trial demonstrate the safety and efficacy of the measles-rubella (MR) vaccination to adults and infants as young as 9 months.